NanoVibronix Regains Nasdaq Compliance
NanoVibronix, Inc. (NAOV) received official notice of compliance from The Nasdaq Stock Market LLC, meeting all criteria for continued listing, including the minimum stockholders' equity requirement of $2.5 million.
Positive
The company has met all applicable criteria for continued listing on The Nasdaq Capital Market.
The minimum stockholders' equity requirement of $2.5 million has been fulfilled.
11/21/2023 - 08:30 AM
ELMSFORD, N.Y. --(BUSINESS WIRE)--
NanoVibronix, Inc $2.5 million
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York , with research and development in Nesher, Israel , focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield®, UroShield® and WoundShield®, all of which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com .
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as, e.g., foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121099399/en/
Investor Contacts:
brett@haydenir.com
Source: NanoVibronix, Inc.
What is the official notice received by NanoVibronix, Inc. (NAOV) from The Nasdaq Stock Market LLC?
The official notice confirms the company's compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the minimum stockholders' equity requirement of $2.5 million.
What are the products produced by NanoVibronix, Inc. (NAOV)?
NanoVibronix, Inc. produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices.
When was the compliance notice received by NanoVibronix, Inc. (NAOV) announced?
The compliance notice was announced on November 20, 2023.
What is the ticker symbol for NanoVibronix, Inc.?
The ticker symbol for NanoVibronix, Inc. is NAOV.
What is the minimum stockholders' equity requirement fulfilled by NanoVibronix, Inc. (NAOV)?
The company has fulfilled the minimum stockholders' equity requirement of $2.5 million for continued listing on The Nasdaq Capital Market.
